CelLBxHealthFRA:DWV Days Payable is 1,356.08 as of Dec. 2025, which is 11% above its 10-year median of 1,226.74. The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 93.16% on this metric.
The historical rank and industry rank for CelLBxHealth's Days Payable or its related term are showing as below:
FRA:DWV'
s Days Payable Range Over the Past 10 Years
Min: 295.57 Med: 1226.74 Max: 5507.97
Current: 806.19
During the past 13 years, CelLBxHealth's highest Days Payable was 5507.97. The lowest was 295.57. And the median was 1226.74.
FRA:DWV's Days Payable is ranked better than 93.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs FRA:DWV: 806.19
CelLBxHealth's Days Payable
increased
from Dec. 2024 (558.72) to Dec. 2025 (1,356.08).
It may suggest that CelLBxHealthdelayed paying its suppliers.
CelLBxHealth Days Payable Related Terms
CelLBxHealth Days Payable Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:DWV vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, CelLBxHealth's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Days Payable distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CelLBxHealth's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CelLBxHealth (FRA:DWV) has a Days Payable of 1,356.08 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CelLBxHealth and its competitors. This is 11% above median its historical median of 1,226.74. Over the past decade, CelLBxHealth's Days Payable has ranged from 295.57 to 5,507.97. According to the industry distribution chart, CelLBxHealth ranks #13 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 6.8%.
Is CelLBxHealth's Days Payable too high?
CelLBxHealth's current Days Payable of 1,356.08 is 11% above median its 10-year median of 1,226.74. Over the past 10 years, this metric has ranged from a low of 295.57 to a high of 5,507.97. The Medical Diagnostics & Research industry median Days Payable is 65.39. CelLBxHealth's value of 1,356.08 is 1974% above this industry median. Based on the distribution chart, CelLBxHealth ranks #13 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does CelLBxHealth's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #13 out of 190 companies for Days Payable. This places CelLBxHealth in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 65.39. CelLBxHealth's value of 1,356.08 is 1974% above this benchmark. Historically, CelLBxHealth's own Days Payable has ranged from 295.57 to 5,507.97 over the past decade. While the company's 10-year median is 1,226.74 vs. the industry median of 65.39, CelLBxHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CelLBxHealth's current Days Payable of 1,356.08 is 1974% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current Days Payable is 1,356.08, which is 11% above median its own 10-year median of 1,226.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 75.7% below its estimated fair value. The current Days Payable is 1,356.08, which is 11% above median its 10-year median of 1,226.74 and 1974% above the Medical Diagnostics & Research industry median of 65.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Days Payable is 1,356.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DWV has been successfully added to your 